Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 12Completed 4Active not recruiting 4Withdrawn 1Terminated 1

Sponsor Class

NIH 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 40Gastrointestinal 40Genitourinary 25Breast 14Other solid neoplasm 8Gynecologic 7Dermatologic 7Lymphoid 6Head & Neck 6CNS 6Tumor-Agnostic 5Sarcoma 4Endocrine 4Other hematologic neoplasm 3NET 1Myeloid 1

Conditions

Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Lymphoma, Follicular 1Chordoma 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 22Specimen Handling 20Magnetic Resonance Spectroscopy 20pembrolizumab 18Nivolumab 18Radiotherapy 17Biopsy 16Doxorubicin 15Temozolomide 14Radiation 14X-Rays 9Irinotecan 9Ipilimumab 9Ifosfamide 9fludarabine 8Phantoms, Imaging 8Etoposide 8cabozantinib 7Vincristine 7Carboplatin 7Bevacizumab 7regorafenib 6Sirolimus 6palbociclib 5olaparib 5fludarabine phosphate 5durvalumab 5Vinorelbine 5Sunitinib 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × atezolizumab × Sarcoma × Clear all
NCT03141684 2026-06-03

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
63 enrolled 1 FDA
Sarcoma

Sarcoma, Alveolar Soft Part

NCT04458922 2026-06-02

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
27 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Clear Cell

NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Amgen

Phase 1 Active not recruiting
610 enrolled
Other solid neoplasmSarcoma

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡